Ozempic injectable pens have quickly become one of the most prescribed drugs for weight loss and diabetes, but few people stay on it long term. Research shows that while nearly half of patients (47.1%) were still filling their prescriptions after one year, only 22.2% continued at two years.
But what happens when you stop taking Ozempic? This isn’t talked about nearly as much, and the reality may surprise you. This article explores that question in depth, looking at research and real-world experiences to understand what truly happens after discontinuation.
What Happens When You Stop Taking Ozempic
Here’s what you can realistically expect after you stop Ozempic (semaglutide):
1. Weight regain that is often substantial
Weight gain after stopping Ozempic is a common occurrence.
Ozempic can lead to weight loss by helping you eat less. It slows how fast food leaves your stomach and reduces appetite signals in your brain. When you’re on it, you naturally take in fewer calories without feeling as hungry.
But once you stop:
Metabolism slows down
After losing weight from Ozempic, your body may burn fewer calories at rest than it did before.
One study showed that cutting calories in half reduced calorie burn by 266 per day, and almost half of that drop came from the body deliberately conserving energy. This “metabolic adaptation” happened within 3 days of calorie restriction.
In another trial, people who cut calories by 25% burned 454 fewer calories/day after 3 months. Those on a stricter low-calorie diet of 890 calories/day burned even less, about 633 fewer calories/day.
On top of that, they moved less without realizing it. This “behavioral adaptation” means the body unconsciously reduces activity to save energy.
Appetite returns
Hormones also shift fast. Leptin, the hormone that signals your brain you’ve got enough stored fat, dropped by 44% in just 3 weeks. With less leptin, your brain thinks you’re low on reserves, even if you still have fat. The result:
-
- hunger goes up
- energy burn goes down
Another study found that ghrelin, the “hunger hormone,” increased by 24% in a day after diet-induced weight loss, pushing people to eat more.
Now you’re hungrier but burning fewer calories, so it’s much easier to regain the lost weight.
While on Ozempic, avoid restricting your calorie intake too much or for too long, and prioritize lifestyle changes such as a balanced diet, regular exercise, and adequate sleep. A study showed that those who combined calorie cutting with exercise (cut calories by 12.5% and exercised enough to burn another 12.5%) didn’t have the same drop in metabolism or activity.
2. Blood sugar control weakens

Direct type-2-diabetes withdrawal data with semaglutide (Ozempic) are limited, but a study on a similar drug (dulaglutide, marketed as Trulicity) showed clear loss of blood sugar control after stopping:
-
- Average HbA1c increased from 7.0% to 8.1% within 3 months of discontinuation.
- Mean fasting glucose went up from 129 mg/dL to 156 mg/dL.
- C-peptide levels (a marker of insulin production) dropped from 4.93 to 3.44 ng/mL.
Stopping Ozempic is likely to lead to a similar outcome.
With Ozempic, your pancreas produces more insulin when blood sugar levels are high and suppresses the release of glucagon (which raises blood sugar). It also slows stomach emptying, so meals raise blood sugar gradually.
After stopping,
-
- insulin release falls
- glucagon is no longer suppressed, and the liver puts more glucose into the blood
- food moves through faster, causing sharper spikes after meals
People with type 2 diabetes already have a weaker gut-to-pancreas signal. Ozempic strengthens that while you’re on it, but once it’s gone, the signal weakens again.
3. Cardiometabolic risk factors return to baseline
Ozempic’s long-term effects go beyond blood sugar and weight. People taking it also experienced greater improvements in cardiovascular risk factors. These included:
-
- lower blood pressure (systolic and diastolic)
- lower C-reactive protein (CRP, an inflammation marker)
- better lipid profile (higher “good” cholesterol and lower “bad” cholesterol, total cholesterol, and triglycerides)
However, these benefits were not maintained after treatment discontinuation.
In the STEP 1 trial extension, blood pressure went back to baseline, and most lipid markers worsened after stopping semaglutide.
| Marker | Baseline (Week 0) | Week 68 (on semaglutide) | Week 120 (after stopping) |
|---|---|---|---|
| Systolic BP (mmHg) | 129 | 121 | 131 (back to baseline) |
| Diastolic BP (mmHg) | 81 | 78 | 82 (back to baseline) |
| Total cholesterol (mg/dL) | 193.4 | 184.6 | 191.4 |
| LDL cholesterol (mg/dL) | 113.4 | 108.2 | 108.5 |
| VLDL cholesterol (mg/dL) | 25.5 | 18.6 | 23.5 |
| Triglycerides (mg/dL) | 131.1 | 95.7 | 122.4 |
| C-reactive protein (mg/L) | 2.95 | 1.28 | 1.83 |
4. Prediabetes improvements can reverse
Doctors sometimes prescribe Ozempic for prediabetes because there’s supportive evidence, even though the FDA hasn’t formally approved it for that use.
In the STEP 1 trial extension, among participants with prediabetes at baseline, 93.6% reverted to normal blood sugar (normoglycemia) with semaglutide. In contrast, only 41.5% of those on placebo returned to normal.
This shows semaglutide was very effective at pushing prediabetes back to healthy glucose levels. Once semaglutide was stopped, the share of participants still in normoglycemia dropped to 43.3%.
5. Side effects commonly resolve
Most day-to-day side effects of Ozempic, like nausea, diarrhea, or constipation, go away after stopping Ozempic as the drug clears your body. However, if you experience a serious complication, such as pancreatitis or gallbladder disease, stopping helps prevent new issues, but the condition itself requires proper medical care.
6. Hypoglycemia risk profile changes if you also use insulin/sulfonylureas
While on Ozempic, combining it with insulin or a sulfonylurea raises hypoglycemia risk, as indicated in its label warning. Stopping Ozempic removes that additive risk, but because glucose will run higher, your care team may adjust other diabetes medications to keep your blood sugar in safe levels.
7. Oral drug absorption returns to usual
Slower stomach emptying means some oral drugs may take longer to start working.
In clinical studies, the delay hasn’t been shown to cause major problems with the most common medicines. However, drugs that need precise timing or fast absorption (like certain antibiotics, thyroid medications, or pain relievers) may be more affected.
In a Reddit post, a user said they had to stop Ozempic because it was interfering with the absorption of their bipolar, PTSD, thyroid, and ADHD medications. They reported worsening irritability and poor mood control despite losing 8 pounds on the drug.
Others described similar issues, such as worsening depression, anxiety, and needing higher doses of antidepressants after starting Ozempic. One commenter suspected Ozempic delayed the effect of their slow-release medication.
Many agreed that while Ozempic helped with weight loss, maintaining mental health and ensuring other medications worked properly had to come first.
How To Stop Taking Ozempic Safely
You won’t go through withdrawal symptoms like with addictive drugs. There’s no need to taper, but it’s important to have a safe plan in place so your blood sugar and weight remain under control.
Here’s how to do it:
Step 1: Before you stop
Plan with your healthcare provider.
Step 2: While stopping
What actually happens when you stop:
Step 3: After stopping
Managing life without Ozempic:
How Long Does Ozempic Stay In Your System After Stopping

Ozempic has a long half-life of about 1 week, and it would take about 5-6 weeks after your last dose for the drug to fully leave your system.
So, even if you stop injections, semaglutide is still active in your body for more than a month. During this time, you may continue to experience some effects, such as a reduced appetite or mild gastrointestinal issues, although these will gradually subside.
Related Articles
How To Prevent Weight Gain After Stopping Ozempic
Here’s how you can reduce the risk of weight regain after stopping Ozempic:
Structure your eating habits
Build an exercise routine
Behavioral & lifestyle supports
Monitor and adjust
In Summary
Once you stop Ozempic, most of its benefits fade.
What happens after you stop Ozempic comes down to preparation. Without Ozempic, you’ll need to lean more heavily on structured eating, regular activity, stress and sleep management, and ongoing medical support. Work closely with your doctor to explore alternatives or personalized lifestyle strategies that can help you transition safely.
Frequently Asked Questions
Sources
Terhune, C. (2024, July 10). Exclusive: Most patients stop using Wegovy, Ozempic for weight loss within two years. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/most-patients-stop-using-wegovy-ozempic-weight-loss-within-two-years-analysis-2024-07-10/
Müller, M. J., Enderle, J., Pourhassan, M., Braun, W., Eggeling, B., Lagerpusch, M., Glüer, C., Kehayias, J. J., Kiosz, D., & Bosy-Westphal, A. (2015). Metabolic adaptation to caloric restriction and subsequent refeeding: the Minnesota Starvation Experiment revisited. American Journal of Clinical Nutrition, 102(4), 807–819. https://doi.org/10.3945/ajcn.115.109173
Redman, L. M., Heilbronn, L. K., Martin, C. K., De Jonge, L., Williamson, D. A., Delany, J. P., & Ravussin, E. (2009). Metabolic and behavioral compensations in response to caloric restriction: Implications for the maintenance of weight loss. PLoS ONE, 4(2), e4377. https://doi.org/10.1371/journal.pone.0004377
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002). Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. The New England journal of medicine, 346(21), 1623–1630. https://doi.org/10.1056/NEJMoa012908
Choe, H. J., Nauck, M. A., & Moon, J. H. (2024). Metabolic consequences of Glucagon-Like peptide-1 receptor agonist shortage: Deterioration of glycemic control in Type 2 diabetes. Endocrinology and Metabolism, 40(1), 156–160. https://doi.org/10.3803/enm.2024.2150
Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes Obesity and Metabolism, 20(S1), 5–21. https://doi.org/10.1111/dom.13129
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2017). Semaglutide improves postprandial glucose and lipid metabolism, and delays first?hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism, 20(3), 610–619. https://doi.org/10.1111/dom.13120
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
Hausner, H., Karsbøl, J. D., Holst, A. G., Jacobsen, J. B., Wagner, F., Golor, G., & Anderson, T. W. (2017). Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clinical Pharmacokinetics, 56(11), 1391–1401. https://doi.org/10.1007/s40262-017-0532-6
Brum, J. M., Gibb, R. D., Peters, J. C., & Mattes, R. D. (2016). Satiety effects of psyllium in healthy volunteers. Appetite, 105, 27–36. https://doi.org/10.1016/j.appet.2016.04.041
Gottlieb, D. J., Punjabi, N. M., Newman, A. B., Resnick, H. E., Redline, S., Baldwin, C. M., & Nieto, F. J. (2005). Association of sleep time with diabetes mellitus and impaired glucose tolerance. Archives of Internal Medicine, 165(8), 863. https://doi.org/10.1001/archinte.165.8.863
Li, Q. (2021). The association between sleep duration and excess body weight of the American adult population: a cross-sectional study of the national health and nutrition examination survey 2015–2016. BMC Public Health, 21(1). https://doi.org/10.1186/s12889-021-10369-9
Kommu, S., & Whitfield, P. (2024, February 11). Semaglutide. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK603723/




